DB-1303-O-1001: A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Condition: Breast Cancer and Endometrial Cancer
Sponsor: DualityBio Inc.
Full Title
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors
Study Treatment
Cohort 2i: HER2 targeting antibody drug conjugate DB-1303/BNT323
Cohort 2l/m: HER2 targeting antibody drug conjugate DB-1303/BNT323 +/- pertuzumab
Eligibility/Info
Cohort 2i: HER2-expressing (IHC 1+ to IHC3+ or ISH+) endometrial cancer treated with 1-3 prior lines of systemic therapy including platinum-based therapy and an immune checkpoint inhibitor.
Cohort 2l/m: HER2-positive (IHC3+ or IHC2+ and ISH+) metastatic breast cancer that has not been treated systemically in the advanced/metastatic setting.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
